| Naked mAbs |
They target tumor cells selectively via Fab terminal based on TAAs, marking them for destruction by immune cells |
High specificity |
- Tafasitamab targeting CD19 |
Expensive, non-specific harmful side effects, including off-target effects and immune reaction, unknown survival rates, and prognoses |
| - Isatuximab targeting CD38 |
| - Margetuximab targeting HER2 |
| BsAbs |
They can bind simultaneously to multiple antigens |
Better anticancer activity through dual functionality |
- Blinatumomab targeting CD19/CD3 |
| - Amivantamab targeting EGFR/METR |
| Immune checkpoint mAbs |
Block inhibitory checkpoints like PD-1 and CTLA-4 to activate immune cells against tumors |
Enhance the immune system's ability to recognize and destroy tumor cells |
- Ipilimumab targeting CTLA-4 for melanoma |
